Centre Leon Berard; Departement Oncologie Medicale

Lyon 69373

0 studies enrolling now · 19 studies all time

What they study most

Advanced Solid Tumors, B-cell Lymphoma, Bladder Cancer, Breast Cancer, Carcinoma, Transitional Cell, Chronic Lymphocytic Leukemia, Colorectal Cancer, Lymphoma, Multiple Myeloma, Neoplasms, Neoplasms, Non-Small Cell Lung Cancer, Sarcoma

Studies at this site

• A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma — Stopped early
• A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) — Completed
• A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection — Stopped early
• A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma — Completed
• A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer — Completed
• A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer — Completed
• A Study of Atezolizumab in Advanced Solid Tumors — Completed
• A Study of R1507 in Participants With Recurrent or Refractory Sarcoma — Stopped early
• A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors — Completed
• A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors — Completed
• A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors — Completed
• A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Completed
• A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] — Completed
• A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors — Completed
• A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors — Completed
• A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors — Completed
• A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers — Completed
• FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients — Completed
• A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma — Stopped early